12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Remicade infliximab regulatory update

Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508, Osaka, Japan) said Japan's Ministry of Health, Labor and Welfare (MHLW) lifted the conditional approval of Remicade infliximab for psoriasis. The chimeric mAb against tumor necrosis factor (TNF) alpha received...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >